Acquisitions, Appointments, Patent Grant, Technical Updates, and Awareness Campaign - Research Reports on Covidien, Biogen Idec, Achillion, Intercept and Mylan

NEW YORK, August 28, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6032-100free.

Covidien plc Research Reports
On August 22, 2014, Covidien plc (Covidien) announced that it has acquired Reverse Medical Corporation, a medical device company dedicated to the management of vascular disease. Covidien stated that the business of Reverse Medical Corporation will be reported as a part of the Company's Neurovascular product line in the Medical Devices segment. "Covidien is focused on technologies that deliver improved patient care through clinically relevant and economically valuable solutions," said Brett Wall, President, Neurovascular, Covidien. "The acquisition of Reverse Medical is complementary to our existing portfolio and will allow us to leverage existing vascular technologies to compete in the worldwide vascular embolization market, which is growing at a double digit rate." The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/COV/report.pdf

Biogen Idec Inc. Research Reports
On August 21, 2014, Biogen Idec Inc. (Biogen Idec) announced that Adriana (Andi) Karaboutis has been appointed as Executive Vice President, Technology and Business Solutions, effective September 24, 2014. Biogen Idec stated that in her new role, Ms. Karaboutis will report to George Scangos, Ph.D, CEO and will lead information technology operations and advance the Company's use of technology and data to enhance overall engagement with patients and healthcare providers. Biogen Idec informed that prior to her new role, Ms. Karaboutis has worked with Dell as Vice President and Chief Information Officer. "Andi is a remarkable technology leader who will enable Biogen Idec to infuse digital innovation at all levels of our business and research organizations," said Dr. Scangos. The full research reports on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/BIIB/report.pdf

Achillion Pharmaceuticals, Inc. Research Reports
On August 19, 2014, Achillion Pharmaceuticals, Inc. (Achillion) announced that the U.S. Patent & Trademark Office has granted the Company U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. According to the Company, ACH-3102 is its second generation Phase 2 NS5A inhibitor being examined for the cure of chronic hepatitis C virus (HCV) infection. Achillion informed that this patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032. Milind Deshpande, President and CEO, Achillion said, "With the issuance of this patent for our differentiated NS5A inhibitor, ACH-3102, along with the previously granted patent for sovaprevir, our NS3/4A protease inhibitor, we are pleased to recognize the talented Achillion team that discovered and has advanced these compounds into Phase 2 trials evaluating their use in all-oral combination regimens for the treatment of chronic HCV." The full research reports on Achillion are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/ACHN/report.pdf

Intercept Pharmaceuticals, Inc. Research Reports
On August 25, 2014, shares in Intercept Pharmaceuticals, Inc. (Intercept) moved up 2.59% to end the day at $294.56, outperforming the S&P 500 Index which gained 0.48% over the same day. During the day, the stock opened at $294.25 and fluctuated within the range of $291.52 and $299.68. As of August 25, 2014, the Company had a market capitalization of $6.09 billion. The full research reports on Intercept are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/ICPT/report.pdf

Mylan Inc. Research Reports
On August 25, 2014, Mylan Specialty, the specialty pharmaceutical business of Mylan Inc. (Mylan), along with Adrian Peterson, Pro Football Player and EpiPen (epinephrine) Auto-Injector Spokesperson Adrian Peterson, announced the three winners of Ready2Go MVP Draft. Mylan stated that the winners also shot an educational video with Peterson, aimed at assisting people identify the signs and symptoms of anaphylaxis and how to respond if it occurs. According to the Company, Ready2Go MVP Draft is a countrywide search to discover kids who have potentially life-threatening allergies and are geared up to respond to the occurrence of life-threatening allergic reaction (anaphylaxis). Mylan informed that Being Ready2Go implies avoiding ones allergic triggers, knowing the signs and symptoms of anaphylaxis, having access to two EpiPen Auto-Injectors and seeking medical help in case of anaphylaxis. Mylan stated that the winners in the 3 categories were: Evan Johnson, in age group 5-9 years from FriscoTexas, Nathaniel Campen in age group 10-13 yrs from Rosemount, Minnesota and Katherine Schug in age group 14-18 years from Scotch Plains, New Jersey. The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/MYL/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review